Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Wj Huizinga

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
RMD Open|December 6, 2023
Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II associationMichelle D van den Beukel, Tineke J van Wesemael, Anna Titia W Hoogslag, et al.
RMD Open|July 15, 2025
Value of the 6 min walk test in detecting cardiopulmonary involvement in patients with systemic sclerosisSaad Ahmed, Sophie I E Liem, Jacopo Ciaffi, et al.
Annals of the Rheumatic Diseases|August 13, 2021
Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RATheresa Kissel, Tineke J van Wesemael, Anders Lundquist, et al.
RMD Open|October 8, 2020
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinibJonathan Kay, Masayoshi Harigai, Josh Rancourt, et al.
Annals of the Rheumatic Diseases|March 7, 2020
Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progressTom Wj Huizinga, V Michael Holers, Jennifer Anolik, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 24, 2015
Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR DatabaseEmilia Gvozdenović, Ron Wolterbeek, Cornelia F Allaart, et al.
Seminars in Arthritis and Rheumatism|April 17, 2025
Rheumatoid arthritis-associated interstitial lung disease in countries across the worldSascha L Heckert, Tjardo D Maarseveen, Emiel R Marges, et al.
Annals of the Rheumatic Diseases|May 16, 2020
Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre studySandra van Bijnen, Jeska de Vries-Bouwstra, Cornelia H van den Ende, et al.
RMD Open|June 28, 2024
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA studyPeter C Taylor, Georg Schett, Tom Wj Huizinga, et al.
Annals of the Rheumatic Diseases|December 20, 2023
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
RMD Open|December 6, 2023
Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II associationMichelle D van den Beukel, Tineke J van Wesemael, Anna Titia W Hoogslag, et al.
RMD Open|July 15, 2025
Value of the 6 min walk test in detecting cardiopulmonary involvement in patients with systemic sclerosisSaad Ahmed, Sophie I E Liem, Jacopo Ciaffi, et al.
Annals of the Rheumatic Diseases|August 13, 2021
Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RATheresa Kissel, Tineke J van Wesemael, Anders Lundquist, et al.
RMD Open|October 8, 2020
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinibJonathan Kay, Masayoshi Harigai, Josh Rancourt, et al.
Annals of the Rheumatic Diseases|March 7, 2020
Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progressTom Wj Huizinga, V Michael Holers, Jennifer Anolik, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 24, 2015
Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR DatabaseEmilia Gvozdenović, Ron Wolterbeek, Cornelia F Allaart, et al.
Seminars in Arthritis and Rheumatism|April 17, 2025
Rheumatoid arthritis-associated interstitial lung disease in countries across the worldSascha L Heckert, Tjardo D Maarseveen, Emiel R Marges, et al.
Annals of the Rheumatic Diseases|May 16, 2020
Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre studySandra van Bijnen, Jeska de Vries-Bouwstra, Cornelia H van den Ende, et al.
RMD Open|June 28, 2024
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA studyPeter C Taylor, Georg Schett, Tom Wj Huizinga, et al.
Annals of the Rheumatic Diseases|December 20, 2023
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, et al.
Pageof 5